Your browser doesn't support javascript.
Homocysteine in coronavirus disease (COVID-19): a systematic literature review.
Carpenè, Giovanni; Negrini, Davide; Henry, Brandon M; Montagnana, Martina; Lippi, Giuseppe.
  • Carpenè G; Section of Clinical Biochemistry and School of Medicine, University of Verona, Verona, Italy.
  • Negrini D; Section of Clinical Biochemistry and School of Medicine, University of Verona, Verona, Italy.
  • Henry BM; Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Montagnana M; Section of Clinical Biochemistry and School of Medicine, University of Verona, Verona, Italy.
  • Lippi G; Section of Clinical Biochemistry and School of Medicine, University of Verona, Verona, Italy.
Diagnosis (Berl) ; 9(3): 306-310, 2022 08 01.
Article in English | MEDLINE | ID: covidwho-1892369
ABSTRACT

OBJECTIVES:

Coronavirus disease 2019 (COVID-19) is a life-threatening infectious disorder characterized by a sustained prothrombotic state. Since homocysteine is a potential biomarker of thrombotic diseases, the aim of this article is to provide an updated overview on the possible role played by hyperhomocysteinemia in influencing an unfavorable COVID-19 progression.

METHODS:

We carried out an electronic search in Medline (PubMed interface) using the keywords ("COVID-19" OR "SARS-CoV-2") AND "homocysteine", between 2019 and the present time, with no language restrictions, to identify all articles which explored the concentration of homocysteine in COVID-19 patients with or without unfavorable disease progression.

RESULTS:

Three studies, totaling 694 hospitalized COVID-19 patients, were included in our systematic review. Overall, the differences between the mean homocysteine values in non-severe vs. severe COVID-19 patients were always positive (i.e., 15.1%, 24.1% and 22.8%, generating a positive weight mean difference of 1.75 µmol/L (95%CI, 1.26-2.25 µmol/L; p=0.011), which translates into a cumulative difference of approximately ∼1.2 µmol/L.

CONCLUSIONS:

Despite the limited evidence that has been garnered so far, increased homocysteine ​​levels may be a potentially useful marker for predicting the risk of unfavorable progression in patients with COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Homocysteine Type of study: Prognostic study / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: Diagnosis (Berl) Year: 2022 Document Type: Article Affiliation country: Dx-2022-0042

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Homocysteine Type of study: Prognostic study / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: Diagnosis (Berl) Year: 2022 Document Type: Article Affiliation country: Dx-2022-0042